Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Change in Accured Expenses (2016 - 2026)

Sunshine Biopharma filings provide 12 years of Change in Accured Expenses readings, the most recent being -$565040.0 for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 132.2% to -$565040.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$189956.0, a 104.77% decrease, with the full-year FY2025 number at -$189956.0, down 104.77% from a year prior.
  • Change in Accured Expenses hit -$565040.0 in Q4 2025 for Sunshine Biopharma, down from $1.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.8 million in Q4 2024 to a low of -$1.0 million in Q2 2023.
  • Median Change in Accured Expenses over the past 5 years was -$46044.0 (2021), compared with a mean of $124379.8.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 6943.87% in 2021 and later plummeted 10997.79% in 2023.
  • Sunshine Biopharma's Change in Accured Expenses stood at -$4378.0 in 2021, then plummeted by 2413.23% to -$110029.0 in 2022, then crashed by 605.41% to -$776161.0 in 2023, then skyrocketed by 326.07% to $1.8 million in 2024, then plummeted by 132.2% to -$565040.0 in 2025.
  • The last three reported values for Change in Accured Expenses were -$565040.0 (Q4 2025), $1.2 million (Q3 2025), and -$363693.0 (Q2 2025) per Business Quant data.